Galderma Research & Development

Galderma Holding Sa

Galderma S.a.

Philippe Martel

Michel Rivier

Johannes Voegel

Philippe Andres

Sandrine Rethore

Nabil Kerrouche

Itaru Suzuki

Laurent Petit

Fabien Audibert

Carole Chomat

Valérie Bourdes

Philippe Reynier

The present invention relates to a combination of ivermectin and brimonidine for use in the treatment and/or the prevention of moderate to severe rosacea, preferably by topical administration of a 1% ivermectin cream and 0.33% brimonidine gel.

Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea

A system comprising a combination of at least one MCI R receptor agonist and a source of NB-UVB, wherein said system is adapted for simultaneous or sequential use of said MC1R receptor agonist and said NB-UVB in amounts effective for the treatment and/or prevention of dermatological conditions linked to a hypopigmentation.

Combination of a MC1R receptor agonist and UVB for the treatment and/or prevention of pigmentation disorders

A combination of compounds is described for the treatment and/or prevention of skin conditions linked to hypopigmentation. Also described, is a combination product that includes at least one prostaglandin receptor agonist and at least one MC1R receptor agonist, as a medicament for use simultaneously, separately or spread out over time for the treatment and/or prevention of skin conditions linked to hypopigmentation, such as vitiligo.

Combination of a prostaglandin receptor agonist and an MC1R receptor agonist for the treatment and/or prevention of pigmentation disorders

Growing community of inventors

Biot, France

Philippe Martel